Compare Cloudflare Inc (NET) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs Novo Nordisk A/S — how do they compare? Cloudflare Inc trades at $314.27 (market cap $101.23B), while Novo Nordisk A/S trades at $44.72 (market cap $200.69B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.98% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| NET | NVO | |
|---|---|---|
Market Cap | $101.23B | $200.69B |
Sector | Technology | Health |
52-Week High | $330.74 | $63.98 |
52-Week Low | $160.16 | $35.29 |
Enterprise Value | $100.60B | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $284.41, up 1.97% with strong analyst support (72.5% buy ratings) and a $342.74 consensus price target. Recent partnerships with OpenAI and AI security innovations drive momentum, though negative net margins and premium valuations (P/S 39.82) pose challenges. Technical indicators show neutral signals with support at $275 and resistance at $292.
Outlook remains growth-focused with AI-driven revenue potential, but profitability concerns and high valuation multiples require careful monitoring. The stock offers upside from analyst targets but faces execution risks in competitive cybersecurity markets.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
